Sir Gregory Winter CBE, FRS

Recipient of the Canada Gairdner International Award, 2013
"For the engineering of humanized monoclonal antibodies and their widespread use in medical therapy, particularly for treatment of cancer and immune disorders"

Medical Research Council, Laboratory of Molecular Biology, Cambridge, UK

Sir Gregory Winter is a member of the Medical Research Council Laboratory of Molecular Biology (LMB) in Cambridge and until recently, served as its Deputy Director. He is now the Master of Trinity College, Cambridge. Sir Gregory Winter graduated from Cambridge University in 1973, specializing in chemistry and biochemistry. He continued his studies with Cambridge University, receiving his PhD in 1976, specializing in protein and nucleic acid sequencing. Sir Gregory Winter is a pioneer in the science of protein engineering, focusing first on enzymes and then antibodies. At the LMB, he invented techniques to humanize rodent antibodies for use as therapeutics (1986), and later to make fully human antibodies (1989) using combinatorial gene repertoires. His inventions are used in about half of the antibody products on the market, including the humanized antibodies Campath-1H, Herceptin, Avastin, Synagis, and the first human antibody (Humira) to be approved by the U.S. Food and Drug Administration. Sir Winter is also an entrepreneur. He is a founder of Cambridge Antibody Technology (1989) and Domantis (2000). Both of these companies pioneered the use of antibody repertoire technologies to make fully human antibody therapeutics. In 2006, Cambridge Antibody Technology Ltd. was acquired by AstraZeneca PLC and Domantis Ltd. by GlaxoSmithKline PLC in 2006. Most recently, Sir Gregory Winter founded Bicycle Therapeutics Ltd., a biotechnology company dedicated to the development of a new generation of biotherapeutics.

Languages